Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.

Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P.

Am J Clin Oncol. 2009 Oct;32(5):509-14. doi: 10.1097/COC.0b013e3181942a1f.

PMID:
19506454
2.
3.

A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.

Hitt R, Hornedo J, Colomer R, Mendiola C, Brandariz A, Sevilla E, Alvarez-Vicent J, Cortés-Funes H.

Semin Oncol. 1995 Dec;22(6 Suppl 15):50-4.

PMID:
8643971
4.

A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.

Steffens TA, Bajorin DF, Chapman PB, Lovett DR, Cody-Johnson BV, Templeton MA, Heelan RT, Wong GY, Portlock CS, Oettgen HF, et al.

Cancer. 1991 Sep 15;68(6):1230-7.

5.

Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma.

Feun LG, Savaraj N, Hurley J, Marini A.

Cancer Invest. 2002;20(3):357-61.

PMID:
12025231
6.
7.

A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.

Bunn PA Jr, Kelly K.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-144-S12-148.

PMID:
9331140
8.

Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.

Frasci G, D'Aiuto G, Comella P, Apicella A, Thomas R, Capasso I, Di Bonito M, Cartenì G, Biglietto M, De Lucia L, Maiorino L, Piccolo S, Bianchi U, D'Aniello R, Lapenta L, Comella G.

Breast Cancer Res Treat. 1999 Aug;56(3):239-52.

PMID:
10573115
9.

A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.

Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA Jr.

Clin Cancer Res. 1999 Nov;5(11):3419-24.

10.

Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.

Daponte A, Ascierto PA, Gravina A, Melucci MT, Palmieri G, Comella P, Cellerino R, DeLena M, Marini G, Comella G; Italian Cooperative Oncology Group.

Cancer. 2000 Dec 15;89(12):2630-6.

PMID:
11135225
11.

Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.

Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-40-S15-43.

PMID:
9346221
12.

Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.

Langer CJ, Millenson M, Rosvold E, Litwin S, McAleer CA, Bonjo CA, Ozols R.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-81-S12-88.

PMID:
9331128
13.

Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study.

Gebbia V, Di Marco P, Borsellino N, Gebbia N, Valerio MR, Fallica G, Tirrito ML, Valenza R, Citarrella P, Benedetti Panici P.

Anticancer Drugs. 2003 Jun;14(5):359-64.

PMID:
12782942
14.

Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.

Langer CJ, Millenson M, O'Dwyer P, Kosierowski R, Alexander R, Litwin S, McAleer CA, Bonjo CA, Ozols R.

Semin Oncol. 1996 Dec;23(6 Suppl 16):35-41.

PMID:
9007119
15.

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.

Atzpodien J, Lopez Hänninen E, Kirchner H, Franzke A, Körfer A, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H.

Eur J Cancer. 1995 Jun;31A(6):876-81.

PMID:
7646914
16.

Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.

Klaassen U, Wilke H, Pari CP, Strumberg D, Harstrick A, Eberhardt W, Becher R, Diergarten K, Seeber S.

Semin Oncol. 1995 Dec;22(6 Suppl 14):7-11.

PMID:
8553083
17.

A phase II study of neoadjuvant biochemotherapy for stage III melanoma.

Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.

Cancer. 2002 Jan 15;94(2):470-6.

18.

Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.

Belli L, LeChevalier T, Gottfried M, Adams D, Ruffie P, LeCesne A, Tete L, Pellae-Cosset B.

Semin Oncol. 1995 Dec;22(6 Suppl 15):29-33.

PMID:
8643967
19.

Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.

Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C.

Anticancer Drugs. 2002 Jun;13(5):497-503.

PMID:
12045461
20.

High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.

Murren JR, DeRosa W, Durivage HJ, Davis C, Makuch R, Portlock CS.

Cancer. 1991 Mar 15;67(6):1514-7.

Supplemental Content

Support Center